211 related articles for article (PubMed ID: 30842496)
1. Effect of ripasudil on diabetic macular edema.
Minami Y; Song YS; Ishibazawa A; Omae T; Ro-Mase T; Ishiko S; Yoshida A
Sci Rep; 2019 Mar; 9(1):3703. PubMed ID: 30842496
[TBL] [Abstract][Full Text] [Related]
2. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Fukushima A; Suganami H; Araie M;
Acta Ophthalmol; 2016 Feb; 94(1):e26-34. PubMed ID: 26338317
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure.
Inoue K; Okayama R; Shiokawa M; Ishida K; Tomita G
Int Ophthalmol; 2018 Feb; 38(1):93-98. PubMed ID: 28063100
[TBL] [Abstract][Full Text] [Related]
4. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
Acta Ophthalmol; 2015 Jun; 93(4):e254-60. PubMed ID: 25487877
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study.
Tanihara H; Kakuda T; Sano T; Kanno T; Imada R; Shingaki W; Gunji R
Adv Ther; 2019 Feb; 36(2):333-343. PubMed ID: 30610614
[TBL] [Abstract][Full Text] [Related]
6. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma.
Komizo T; Ono T; Yagi A; Miyata K; Aihara M
Jpn J Ophthalmol; 2019 Jan; 63(1):40-45. PubMed ID: 30368633
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma.
Kusuhara S; Katsuyama A; Matsumiya W; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):809-814. PubMed ID: 29468405
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy.
Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
J Glaucoma; 2017 Feb; 26(2):96-100. PubMed ID: 27661993
[TBL] [Abstract][Full Text] [Related]
9. Increase in the OCT angiographic peripapillary vessel density by ROCK inhibitor ripasudil instillation: a comparison with brimonidine.
Chihara E; Dimitrova G; Chihara T
Graefes Arch Clin Exp Ophthalmol; 2018 Jul; 256(7):1257-1264. PubMed ID: 29520478
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study.
Tanihara H; Kakuda T; Sano T; Kanno T; Gunji R
BMC Ophthalmol; 2020 Jul; 20(1):275. PubMed ID: 32646383
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months.
Tanihara H; Kakuda T; Sano T; Kanno T; Kurihara Y
Adv Ther; 2022 Apr; 39(4):1659-1677. PubMed ID: 35150417
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Long-Term Ripasudil 0.4% Instillation for the Reduction of Intraocular Pressure in Japanese Open-Angle Glaucoma Patients.
Maruyama Y; Ikeda Y; Mori K; Yoshii K; Ueno M; Sotozono C; Kinoshita S
J Ocul Pharmacol Ther; 2020 May; 36(4):229-233. PubMed ID: 32175792
[No Abstract] [Full Text] [Related]
13. Intraocular pressure-lowering effects of Ripasudil: a potential outcome marker for Trabeculotomy.
Goda E; Hirooka K; Mori K; Kiuchi Y
BMC Ophthalmol; 2019 Dec; 19(1):243. PubMed ID: 31791272
[TBL] [Abstract][Full Text] [Related]
14. Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy.
Sato S; Hirooka K; Nitta E; Ukegawa K; Tsujikawa A
Adv Ther; 2016 Sep; 33(9):1628-34. PubMed ID: 27438467
[TBL] [Abstract][Full Text] [Related]
15. The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15.
Sakata R; Fujishiro T; Saito H; Honjo M; Shirato S; Aihara M
Adv Ther; 2021 Jul; 38(7):3760-3770. PubMed ID: 34028695
[TBL] [Abstract][Full Text] [Related]
16. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.
Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2009-2015. PubMed ID: 28711991
[TBL] [Abstract][Full Text] [Related]
17. Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
JAMA Ophthalmol; 2015 Jul; 133(7):755-61. PubMed ID: 25880207
[TBL] [Abstract][Full Text] [Related]
18. Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension.
Theodoropoulou S; Ellabban AA; Johnston RL; Cilliers H; Mohamed Q; Sallam AB
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):725-732. PubMed ID: 27878430
[TBL] [Abstract][Full Text] [Related]
19. Ripasudil: first global approval.
Garnock-Jones KP
Drugs; 2014 Dec; 74(18):2211-5. PubMed ID: 25414122
[TBL] [Abstract][Full Text] [Related]
20. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.
Bressler SB; Almukhtar T; Bhorade A; Bressler NM; Glassman AR; Huang SS; Jampol LM; Kim JE; Melia M;
JAMA Ophthalmol; 2015 May; 133(5):589-97. PubMed ID: 25719991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
